Tasly Pharmaceutical Group (600535.SH): Clinical trial approved for extending the time window for the indication of recombinant human urine plasminogen activator for acute ischemic stroke.

Tasly Pharmaceutical Group (600535.SH) announced that its wholly owned subsidiary Tasly Pharmaceutical Group Biopharmaceutical Co., Ltd. (referred to as "Tasly Pharmaceutical Group Biopharmaceutical") recently received the approval and issuance of a clinical trial notification from the National Medical Products Administration for the company's biologic innovative drug - recombinant human urinary tissue-type plasminogen activator (Puyouke) with independent intellectual property rights. The approval allows for the conduct of clinical trials for the treatment of acute ischemic stroke patients within 4.5 to 24 hours of onset. Puyouke is a type 1 biologic innovative drug supported by the national major special project for the creation of new drugs. The drug has been approved for the indications of acute ST-segment elevation myocardial infarction and acute ischemic stroke, with the previous indication for acute ischemic stroke limited to patients within 4.5 hours of onset.